Alnylam Pharmaceuticals (ALNY) FCF Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) FCF Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -5,426.00 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 9,545.00 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 4,612.00 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -3,088.00 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 14,060.00 |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | -176.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4,612.00 |
| Mar 31, 2026 | 6,066.00 |
| Dec 31, 2025 | 5,864.00 |
| Sep 30, 2025 | 7,700.00 |
| Jun 30, 2025 | 7,670.00 |
| Mar 31, 2025 | -34,229.00 |
| Dec 31, 2024 | 4,905.00 |
| Sep 30, 2024 | 9,321.00 |
| Jun 30, 2024 | 7,795.00 |
| Mar 31, 2024 | 12,328.00 |
| Dec 31, 2023 | 7,828.00 |
| Sep 30, 2023 | 14,314.00 |
| Jun 30, 2023 | 12,270.00 |
| Mar 31, 2023 | 21,069.00 |
| Dec 31, 2022 | 28,169.00 |
| Sep 30, 2022 | 26,228.00 |
| Jun 30, 2022 | -65,991.00 |
| Mar 31, 2022 | 60,985.00 |
| Dec 31, 2021 | 82,715.00 |
| Sep 30, 2021 | 954,334.00 |